Find out how your research reagents could bring extra funding into your institution
Got any research reagents hanging around
in your fridge?
If you are an MRC-employed scientist we could license your useful research reagents and tools, and help bring in extra funding for MRC research.
We have strong relationships with many reagent companies, including Abcam and Serotec. Our Reagents Catalogue currently contains over 200 reagents, and we are constantly on the lookout for more. These could be monoclonal or polyclonal antibodies, novel expression systems, cell lines or mice.
How does it work?
Once you tell us about your reagent, we approach distributors on your behalf who will sell it around the world. If we are successful, you just need to send the reagents off to the company and they will do the rest.
For further information
If you have a reagent to tell us about, please fill in the appropriate reagent disclosure form and return it to us.
If you would like further information about the Reagents Catalogue, please speak to your Business Manager, or Contact Us and we’ll put you in touch.
News feed
MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.
Aptuscan, a spin out company based on research carried out at the MRC Cancer Cell Unit, has been acquired by Avacta, an AIM-listed biotechnology company.
MRC Technology announced today that they have entered into an agreement with the Association for International Cancer Research (AICR) to assist in the oversight and management of intellectual property (IP) arising from AICR-funded projects.